Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model | Zendy

Deborah F. Chapman | Zendy; Patrick D. Lyden | Zendy; Paul A. Lapchak | Zendy; Sonia Nunez | Zendy; Harold Thibodeaux | Zendy; Justin A. Zivin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model

Author(s) -

Deborah F. Chapman,

Patrick D. Lyden,

Paul A. Lapchak,

Sonia Nunez,

Harold Thibodeaux,

Justin A. Zivin

Publication year - 2001

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.32.3.748

Subject(s) - medicine , tenecteplase , thrombolysis , plasminogen activator , tissue plasminogen activator , stroke (engine) , intracerebral hemorrhage , fibrin , anesthesia , subarachnoid hemorrhage , immunology , mechanical engineering , myocardial infarction , engineering

Tissue plasminogen activator (tPA) is an effective treatment for stroke, but its utility is limited by fear of cerebral hemorrhage. Tenecteplase (TNK), a genetically modified form of wild-type tPA, exhibits a longer biological half-life and greater fibrin specificity, features that could lead to fewer cerebral hemorrhages than wild-type tPA in stroke patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research